Roxadustat (symptomatic anaemia associated with chronic kidney disease (CKD))

Subject:

• Active Substance: Roxadustat
• Name: Evrenzo^®
• Therapeutic area: Anaemia
• Pharmaceutical company: Astellas Pharma GmbH

Time table:

• Start: 15.09.2021
• Final decision by G-BA: 03.03.2022

Final decision:

• No additional benefit proved